Key findings reveal that in gastric cancer, NUTM2A-AS1 functions as a ceRNA for miR‐376a, leading to upregulation of TET1 and HIF-1A and subsequent increase in PD-L1 expression, while also modulating matrine resistance via the miR‐613/ROS/VEGFA axis. Here, NUTM2A is linked to gastric cancer.